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1015-9584/Copyright ª 2013, Asian S
BY-NC-ND license (http://creativecoSummary Hepatobiliary involvement by malignant lymphoma is usually a secondary manifes-
tation of systemic disease, whereas primary non-Hodgkin’s lymphoma of the extrahepatic
biliary ducts is an extremely rare entity. We describe the case of a 57-year-old man who pre-
sented with an acute onset of obstructive jaundice and severe itching. Abdominal ultrasonog-
raphy and computed tomography revealed intrahepatic and common hepatic ducts dilatation.
Magnetic resonance cholangiopancreatography and endoscopic retrograde cholangiopancrea-
tography showed a mid-common bile duct stricture. The patient was presumed to have cholan-
giocarcinoma of the common bile duct, and an en bloc resection of the tumor with Roux-en-Y
hepaticojejunostomy and porta-hepatis lymph nodes dissection was performed. Histopatholo-
gy and immunohistochemistry revealed a large B cell non-Hodgkin’s lymphoma. The patient
received six cycles of combination chemotherapy using cyclophosphamide, vincristine, predni-
sone, and rituximab (CVP-R) protocol, and after a 5-year follow-up he is still in complete remis-
sion. We also reviewed the cases published from 1982 to 2012, highlighting the challenges in
reaching a correct preoperative diagnosis and the treatment modalities used in each case.
Copyright ª 2013, Asian Surgical Association. Published by Elsevier Taiwan LLC. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
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urgical Association. Published by
mmons.org/licenses/by-nc-nd/4.1. Introduction
Non-Hodgkin’s lymphoma (NHL) accounts for 1e2% of all
cases of malignant biliary obstruction.1 To our knowledge
and after reviewing the literature since the first case was
published by Nguyen2 in 1982, only 28 cases have been
reported. Herein we present another case of primary NHL ofElsevier Taiwan LLC. This is an open access article under the CC
0/).
82 A. Zakaria et al.the common bile duct. A literature review was conducted of
the challenges in arriving at the diagnosis preoperatively and
the debate around the optimal treatment modalities.2. Case report
A 57-year-old man with no previous chronic medical ill-
nesses presented with a 2-week history of severe itching all
over his body, associated with general fatigue, malaise, and
nausea, without vomiting or anorexia. He also reported
having a yellowish discoloration of sclera, dark (tea color)
urine, and a bulky foul-smelling stool. However, he denied
any history of fever or chills, abdominal pain, previous
episodes of similar symptoms, recent travels, or contact
with sick people. He is not on any regular medications, and
he denied recent ingestion of any drug. His surgical history
and family history showed no significant finding. Moreover,
he has a 40 pack-year smoking history but no history of
alcohol consumption or illicit drug use.
On presentation his vital signs were within normal limits.
The physical examination revealed deep scleral and skin
jaundice with itching marks on his skin. There was no cer-
vical lymphadenopathy and no stigmata of chronic liver
disease. An abdominal examination revealed a soft and lax
abdomen with mild tenderness over the epigastric and right
upper quadrant areas, and active bowel sounds but no
masses or hepatosplenomegaly.
His laboratory results showed hemoglobin, white cell
count, and platelets of 15 g/dL, 7  103/mm3, and
162  103, respectively. His serum total bilirubin, direct
bilirubin, alanine aminotransferase, aspartate aminotrans-
ferase, alkaline phosphatase, gamma glutamyl trans-
peptidase, lactate dehydrogenase, and amylase results
were 18.3 mg/dL 16.1 mg/dL, 116 U/L, 66 U/L, 161 U/L,
658 U/L, 898 U/L, and 58 U/L, respectively. His blood
carbohydrate antigen 19-9 level rose to more than 1200 U/
mL, and carcinoembryonic antigen was within normal levels
at 0.88 ng/mL. Hepatitis A, B, and C serology was negative.
Abdominal ultrasonography revealed dilated common
hepatic and intrahepatic ducts. An endoscopic retrograde
cholangiopancreatography (ERCP) was subsequently per-
formed and showed a 3-cm mid-common bile duct strictureFigure 1 Imaging studies. (A) Endoscopic retrograde cholangiop
(B) Computed tomography scan of the abdomen showing intra
angiopancreatography showing the tapered stricture of the distalwith significantly dilated intrahepatic and common hepatic
biliary ducts. The rushing cytology of the common bile duct
was suspicious for malignancy. A 9-cm, 10 F stent was
inserted across this for drainage (Fig. 1A).
The abdominal computed tomography (CT) scan
revealed a mild intrahepatic biliary tree dilatation but was
otherwise unremarkable (Fig. 1B).
Magnetic resonance cholangiopancreatography showed a
marked tapered stricture at the distal common bile duct
with mild to moderate dilatation of biliary tree proximally,
and a normal pancreatic duct (Fig. 1C).
Based on the above presentation and investigations, a
presumptive diagnosis of cholangiocarcinoma was made,
and extrahepatic biliary tract excision, a Roux-en-Y hep-
aticojejunostomy, and porta-hepatis lymph nodes excision
were performed.
A histopathologic examination of the common bile duct
revealed a large B cell-type NHL with tumor-free surgical
resection margins (Fig. 2), and the porta-hepatis lymph
nodes showed a reactive nonspecific hyperplasia. Immu-
nohistochemical staining was positive for CD3, CD5, CD20,
CD45, BCL2, and Ki67, and negative for CD15 and CD30
(Fig. 3).
The patient was referred to the oncology clinic, where a
positron emission tomography showed no evidence of ma-
lignant lesions. He received six cycles of chemotherapy
using the CVP-R (cyclophosphamide, vincristine, predni-
sone, and rituximab) protocol. One-year follow-up chest,
abdomen, and pelvis CT and whole-body positron emission
tomography scans revealed no evidence of malignancy. He
received six maintenance courses of rituximab (anti-CD20)
and remains in complete remission 5 years from the time of
diagnosis with a normal whole-body CT scan.3. Discussion
Diffuse large B cell lymphoma (DLBCL) is the most common
lymphoid neoplasm and the most common histologic sub-
type of NHL, accounting for approximately 25% of all
cases.3 It has an overall incidence rate of 3e7 cases per
100,000 persons per year. The incidence also increases with
age (median age 64 years), and the disease appears to beancreatography showing the mid common bile duct stricture.
hepatic bile tract dilatation. (C) Magnetic resonance chol-
common bile duct.
Figure 2 Histopathology of the common bile duct showing
proliferating lymphocytes of medium to large size, in a back-
ground of eosinophils, neutrophils, and reactive T cell lym-
phocytes. Many mitotic figures and apoptotic bodies are seen.
Primary non-Hodgkin’s lymphoma of common bile duct 83slightly more predominant in men (55% of cases) and
Caucasian Americans.4 DLBCL typically presents with rapid
nodal enlargement in the neck or abdomen, and systemic
“B” symptoms are observed in 30% of patients.5 The
extranodal extramedullary disease occurs in up to 40% of
the cases, and the gastrointestinal tract is the mostFigure 3 Immunohistochemistry showing (A) positive CD20, a m
reflecting a high grade; (C) negative CD15, a marker of Hodgkin’s lycommon site of involvement. In such cases, the presenting
symptoms are abdominal pain, loss of appetite, weight loss,
vomiting, and night sweats.6
Among all patients with malignant biliary obstruction,
NHL accounts for 1e2% of all cases. Their presentation with
obstructive jaundice is mostly secondary to compression of
the extrahepatic bile ducts by periportal, perihepatic, or
peripancreatic lymphadenopathy, associated tumor lysis, or
direct hepatic involvement.1
It is extremely rare for NHL to arise primarily from the
extrahepatic bile ducts. As shown below in (Table 1),2,7,9e34
a literature review of the period between 1982 and 2012
revealed only 28 cases, with an acute onset of obstructive
jaundice being the presenting symptom in most. Of note is
that only one case presented with a picture of acute
pancreatitis.
In all cases reviewed, including the one reported above,
the clinical presentation, the laboratory investigations, and
the results of CT and cholangiography were more consistent
with sclerosing cholangitis, Klatskin tumor (chol-
angiocarcinoma at the hepatic duct bifurcation), or
pancreatic carcinoma.
It is very difficult to diagnose primary lymphoma of the
extrahepatic bile ducts on the basis of CT scan, magnetic
resonance imaging, and cholangiography results. However,
Yoon et al7 suggested that despite the paucity of publishedarker of B cell lymphoma; (B) positive Ki67 in 80% of the slide
mphoma; (D) negative CD30, a marker of Hodgkin’s lymphoma.
Table 1 Literature review of primary NHL of the biliary ducts between 1982 and 2012.2,7,9e34
Case Author Age (y)/
sex
Preliminary diagnosis Histopathologic diagnosis Treatment modality Outcome
1 Nguyen2 59/male Sclerosing
cholangitis
Lymphohistiocytic lymphoma,
diffuse type
Surgery
Chemotherapy
Died after 8 mo
2 Takehara et al11 60/male Non-Hodgkin’s lymphoma of the
extrahepatic duct
Surgery
Chemotherapy
Unknown
3 Kaplan et al12 42/male Cholangitis High-grade non-Hodgkin’s
lymphoma
Surgery: Cholecystectomy,
segmental resection of the CBD,
and hepaticoduodenostomy
Chemotherapy using
cyclophosphamide, vincristine,
etoposide, methotrexate,
and cytosine arabinoside
Died after 10 mo
4 Tartar and Balfe13 48/male Bile duct wall lymphoma Surgery
Chemotherapy
Alive after 14 mo
5 Tzanakakis et al14 70/male Mixed small and large cell
non-Hodgkin’s lymphoma
Surgery
Chemotherapy
Died after 4 mo
6 Kosuge et al15 68/female B cell lymphoma of the CBD Surgery
Chemotherapy
Radiotherapy
Died after 16 mo
7 Brouland et al16 34/female GB carcinoma vs.
sclerosing cholangitis
T cell-rich B cell lymphoma
(centroblastic type) of the CBD
Surgery
Chemotherapy using MACOP-B
Alive after 48 mo
8 Machado et al17 43/female Bile duct lymphoma Surgery
Radiotherapy
Alive after 6 mo
9 Chiu et al18 25/female Malignant lymphoma of the bile
duct
Surgery Died after 12 mo
10 Andre et al19 44/female Klatskin tumor Non-Hodgkin’s lymphoma of the
extrahepatic duct
Surgery
Chemotherapy
Alive after 48 mo
11 Maymind et al20 39/female Diffuse large B cell lymphoma of
the CBD
Surgery
Chemotherapy using six courses of
CHOP protocol
Radiotherapy
Alive after 13 mo
12 Podbielski et al21 66/male Klatskin tumor vs.
sclerosing cholangitis
Large B cell non-Hodgkin’s
lymphoma
Surgery: En bloc resection of the
tumor
Unknown
13 Oda et al22 58/male Non-Hodgkin’s lymphoma of the
extrahepatic duct
Surgery Died after 32 d
14 Corbinais et al23 29/male High-grade T cell non-Hodgkin’s
lymphoma of the CBD
Chemotherapy using COP plus
CHOP protocol
Alive after 12 mo
15 Eliason and Grosso24 41/male Klatskin tumor Diffuse large B cell lymphoma of
the extrahepatic ducts
Surgery: CBD excision, Roux-en-Y
hepaticojejunostomy, and
cholecystectomy
Unknown
84
A
.
Z
a
ka
ria
e
t
a
l.
16 Gravel et al25 4/male Sclerosing cholangitis,
histiocytosis X or
lymphoma
Lymphoblastic lymphoma of the
pre-B type of the biliary ducts
Surgery: Exploratory laparotomy,
incisional biopsy of the GB, and
then cholecystectomy
Chemotherapy using
methotrexate, vincristine,
doxorubicin, and prednisone
Alive after 18 mo
17 Kang et al26 73/female Pancreatic vs.
cholangiocarcinoma
Low-grade B cell lymphoma of
MALT type
Surgery: Whipple’s operation Alive after 23 mo
18 Ferluga et al27 3/female Klatskin tumor Grade II follicular lymphoma of the
GB, cystic duct and CBD
Surgery: Resection of GB and CBD
followed by hepaticojejunostomy
Alive after 36 mo
19 Suzuki et al28 71/female Bile duct carcinoma MALT lymphoma of the CBD Surgery: Pylorus-preserving
pancreaticoduodenectomy
Unknown
20 Joo et al9 21/female Bile duct
cholangiocarcinoma
Diffuse large B cell malignant
non-Hodgkin’s lymphoma
Surgery
Chemotherapy using CHOP
protocol
Radiotherapy using 3060 cGy
external irradiation
Alive after 17 mo
21 Sugawara et al29 33/male Hepatic hilar
cholangiocarcinoma
Follicular lymphoma of the
extrahepatic duct
Surgery: Extrahepatic duct
resection with right and left
hepaticojejunostomy
Alive after 12 mo
22 Shito et al30 71/male Klatskin tumor MALT lymphoma of the main
hepatic duct junction
Surgery: Left hepatic and caudate
lobectomy, bile duct resection
and LN dissection
Chemotherapy using three courses
of CHOP protocol
Alive after 45 mo
23 Dote et al10 63/male Pancreatic head
carcinoma or
cholangiocarcinoma
of the CBD
Diffuse large B cell non-Hodgkin’s
lymphoma of the CBD
Surgery: Subtotal stomach-
preserving
pancreaticoduodenectomy
Chemotherapy using three courses
of R-CHOP protocol
Alive after 8 mo
24 Christophides et al31 53/female Infiltrative
cholangiocarcinoma
vs. hepatocellular
carcinoma
High-grade follicular lymphoma
(grade 3A) of the extrahepatic
ducts
Surgery: Extended right
hepatectomy and Roux-en-Y
hepaticojejunostomy
Chemotherapy using CHOP-R
protocol
Alive after 48 mo
25 Kang et al32 60/male Klatskin tumor Diffuse large B cell non-Hodgkin’s
lymphoma of the CHD
Surgery: CHD excision, Roux-en-Y
hepaticojejunostomy and LN
dissection
Chemotherapy: Adjuvant
chemotherapy was scheduled
Unknown
26 Yoon et al7 62/male Cholangiocarcinoma
of the bile duct
Marginal zone B cell lymphoma of
the MALT type
Surgery: Right hemihepatectomy,
bile duct resection and LN
resection
Unknown
(continued on next page)
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86 A. Zakaria et al.cases, radiologists should raise the possibility of primary
biliary tree lymphoma when cholangiography shows smooth,
mild luminal narrowing of the extrahepatic ducts without
mucosal irregularities, in spite of the diffuse thickening of
the ductal wall on CT/magnetic resonance images.
It is crucial to differentiate primary NHL of the bile ducts
from other causes of obstructive jaundice, as the treatment
approach and prognosis are fundamentally different. There
have been recent reports of success with endoscopic
ultrasound-guided fine-needle aspiration biopsy (EUS-FNAB)
in reaching a definitive tissue diagnosis, thus avoiding the
surgical interventions that were performed in almost all of
the reported cases for lymphomas mistakenly thought to be
chemotherapy- or radiotherapy-resistant malignancies.8
In our case, the patient’s clinical presentation, high
level of carbohydrate antigen 19-9, a mid-common bile
duct stricture on ERCP, brush cytology suspicious for ma-
lignant cells, and a dilated common bile duct on CT scan
were consistent with cholangiocarcinoma of the bile duct.
It was only upon surgical resection of the tumor and his-
topathologic as well as immunohistochemical examination
of the specimens that a definitive diagnosis of high-grade B
cell-type NHL of the common bile duct was made.
DLBCL is an aggressive form of lymphoma, and its pri-
mary extranodal involvement of the common bile duct is an
extremely rare disease. There is therefore unfortunately no
consensus on the best treatment modality to be used. Joo
et al9 and Dote et al10 suggest that surgery is important for
establishing the diagnosis and removing the lymphoma, and
that subsequent chemotherapy and/or radiotherapy after
the initial surgery might be effective.
Our case revealed that surgical resection of the tumor
for definitive tissue diagnosis followed by a combination of
chemotherapy using six cycles of CVP-R, maintain the pa-
tient in a complete remission for more than 5 years. How-
ever, further follow-up and more studies are required to
further elucidate the most appropriate treatment modality.
In conclusion, although primary NHL of the biliary ducts
is an extremely rare disease, it should be considered in the
differential diagnosis of malignant obstructive jaundice. A
tissue biopsy by either EUS-FNAB or surgical intervention
showing a characteristic histopathologic and immunohisto-
chemical findings is the gold standard for definitive diag-
nosis. The best treatment modality is still to be identified,
although surgical resection of the tumor followed by
chemotherapy and/or radiotherapy is considered an
effective option.References
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